BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib
October 10, 2016 at 02:39 AM EDT
* Ipsen and its partner Exelixis announce positive results from Phase 2 CABOSUN Trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma
